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Objectives. This study sought to determine whether the dura-
tion of pretreatment with the adenosine diphosphate receptor
antagonist ticlopidine prior to intracoronary stenting is associ-
ated with the incidence of procedure-related non–Q-wave myocar-
dial infarctions (MIs).
Background. Dual antiplatelet therapy with ticlopidine and
aspirin is routinely used with stenting, although ticlopidine is
commonly not begun until the day of the procedure. Periproce-
dural MIs are at least partially platelet-dependent events. As the
maximal platelet inhibitory effects of this drug take 2 to 3 days to
be realized, we hypothesized that longer treatment prior to
stenting would be associated with lower rates of procedure-related
MIs.
Methods. We reviewed outcomes in 175 consecutive patients
treated with ticlopidine prior to stenting at the Cleveland Clinic
Foundation. Those patients with an elevation in creatine kinase
above our laboratory normal (>210 IU/L) with >24% MB fraction
on routine evaluation were defined as having a non–Q-wave MI.
Results. There were 28 patients (16%) who had a non–Q-wave
MI. Longer duration of ticlopidine pretreatment was strongly
associated with a lower incidence of procedure-related non–Q-
wave MIs (duration of pretreatment <1 day, 29% had MI; 1 to 2
days, 14%; >23 days, 5%; chi-square for trend 5 9.6; p 5 0.002).
Ticlopidine pretreatment of >23 days was associated with a
significant reduction in the risk of non–Q-wave MI (unadjusted
odds ratio 0.18, 95% confidence interval 5 0.04 to 0.78, p 5 0.01)
compared with pretreatment of <3 days.
Conclusions. Among patients undergoing intracoronary stent-
ing, beginning ticlopidine therapy several days prior to the
procedure is associated with a reduced risk of procedural non–Q-
wave MIs.
(J Am Coll Cardiol 1998;32:1366–70)
©1998 by the American College of Cardiology
Non–Q-wave myocardial infarctions (MIs) can occur in up to
one-third of patients after percutaneous coronary revascular-
ization procedures (1). Although the clinical significance of
these events is controversial, recent studies involving .10,000
patients in aggregate have suggested that even seemingly
minor elevations in myocardial enzymes after percutaneous
transluminal coronary angioplasty (PTCA) are associated with
increased late mortality, a higher risk of subsequent cardiac
events, and higher costs (2–4). The mechanism behind the
myonecrosis associated with percutaneous revascularization
procedures is at least in part distal embolization. Observational
reports of high rates of periprocedural infarcts in thrombus-
laden lesions support platelet-rich thromboemboli as a major
source of the embolic debris (5), and animal studies have
confirmed that intracoronary platelet microaggregates can lead
to MI (6). However, some of the most compelling evidence
supporting platelet thromboemboli as a major contributor to
procedure-related infarcts comes from angioplasty trials utiliz-
ing aggressive platelet inhibition with glycoprotein (GP) IIb/
IIIa receptor antagonists (7–11). In these trials patients treated
with GPIIb/IIIa inhibitors experienced up to a 50% decrease in
periprocedural MIs compared with those receiving standard
aspirin and heparin therapy.
Patients undergoing coronary stent implantation may be at
increased risk of a non–Q-wave MI than those treated with
balloon angioplasty alone due to increased platelet activation
caused by the intracoronary metallic stent (12,13). This con-
tention is supported by a recent report of a greater than 20%
incidence of non–Q-wave MI in stent-treated patients—nearly
70% greater than that observed in those treated with balloon
angioplasty alone (14,15).
Almost all stent-treated patients today receive combination
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antiplatelet therapy with ticlopidine and aspirin because of its
established benefit in the prevention of stent thrombosis (16).
This combination provides a synergistic inhibition of platelet
aggregation (17,18), although it does not achieve its full
inhibitory potential until after 3 to 5 days of therapy due to the
delayed onset of ticlopidine’s antiplatelet effects (19). Since
subacute stent thrombosis typically occurs at 5 to 6 days after
stent implantation (20), beginning ticlopidine at the time of the
procedure provides adequate protection from this complica-
tion. However, this dosing regimen is unable to provide
additional antiplatelet protection at the time of the procedure,
and therefore is unable to potentially further decrease the risk
of periprocedural complications including non–Q-wave MIs.
We postulated that patients receiving chronic aspirin ther-
apy who were also pretreated with ticlopidine for several days
prior to stenting would experience a decreased incidence of
procedural non–Q-wave MIs due to the time-dependent de-
velopment of enhanced platelet inhibition at the time of stent
implantation. To test this hypothesis we performed an analysis
of consecutive patients at our institution who received an
intracoronary stent and ticlopidine pretreatment of variable
duration before the procedure.
Methods
Patient sample. All data analyzed in this study were
obtained prospectively; demographic, procedural and outcome
information about all patients undergoing percutaneous coro-
nary revascularization procedures at the Cleveland Clinic
Foundation are prospectively entered into an electronic data-
base. All patients provide informed consent before the proce-
dure. From this database, 1,207 consecutive patients were
identified who had an intracoronary stent placed between
August 1995 and December 1996. From this cohort, 103
patients who underwent a concomitant atherectomy were
eliminated due to their recognized association with an in-
creased incidence of non–Q-wave MIs. Another 38 patients
with an MI within the preceding 24 h were also excluded.
Eighty-four patients were excluded for receiving a stent as a
bailout indication, and another 207 patients were excluded for
abciximab treatment. From the remaining 775 patients, 175
received preprocedural ticlopidine. Confirmation of pretreat-
ment and determination of the duration of pretreatment was
through medical record review. These 175 patients were di-
vided a priori into three groups based on the duration of
ticlopidine pretreatment: $3 days before the procedure, 1 to 2
days, or ,1 day if started prior to but on the same day as stent
placement.
Ascertainment of procedure-related MI. Creatine kinase
(CK) levels are routinely and systematically measured at our
institution among all patients undergoing coronary interven-
tion at 8 h and the morning (12 to 25 h) postprocedure.
Creatine kinase MB isoenzyme levels are determined in all
patients with CK levels above 100 IU/L. For the purposes of
this study, any elevation in CK levels above our laboratory’s
normal range (210 IU/L) with an MB fraction of $4% was
considered diagnostic for a non–Q-wave MI.
Statistical methods. The association between duration of
ticlopidine pretreatment and occurrence of procedural non–
Q-wave MI was tested using the Mantel–Haenszel extension
test for trend (21). Because patients who received shorter
durations of ticlopidine pretreatment were more likely to have
B2 or C lesions, to undergo stenting of saphenous vein grafts
and to have had a recent MI, stratified analyses were per-
formed, again using the extension test. Logistic regression
analyses (22) were also used to adjust for potential confound-
ers. No more than two covariates were considered in each
model in order to avoid overfitting. Considered significant
were p values of ,0.05. All analyses were performed using the
SAS 6.12 system (SAS Inc.).
Results
Of the 175 patients studied, 52 patients first received
ticlopidine on the same day as the procedure, 78 patients 1 or
2 days before and 45 patients for 3 or more days. Patients
receiving ticlopidine pretreatment were distributed among all
interventional cardiologists at our institution. The baseline
characteristics of the patients comprising each group are noted
in Table 1. Patients receiving $3 days of ticlopidine were more
frequently diabetic, smokers and had unstable angina, but they
also had shorter average lesion lengths, fewer recent MIs
(within 1 to 7 days), fewer saphenous vein graft lesions and less
frequent modified American College of Cardiology/American
Abbreviations and Acronyms
ADP 5 adenosine diphosphate
GPIIb/IIIa 5 glycoprotein IIb/IIIa
PTCA 5 percutaneous transluminal coronary angioplasty
Table 1. Baseline Patient, Procedural and Lesion Characteristics
According to Duration of Ticlopidine Pretreatment
Duration of Ticlopidine Pretreatment
0 Days 1–2 Days $3 Days
No. of patients 52 78 45
Mean age (yr) 62 61 59.5
Mean LVEF (%) 53.1 53.8 53.8
Unstable angina (%) 57.7 76.9 68.9
Recent MI (%) 19.2 15.4 6.7
Diabetes (%) 15.4 25.6 31.0
Current smoker (%) 17.3 17.9 26.6
Previous bypass (%) 28.8 33.3 31.1
Average no. of treated vessels 1.7 1.6 1.5
Vein graft target vessel (%) 25.0 26.9 20.0
Restenotic lesion (%) 13.5 2.6 15.5
B2 or C lesion (%) 61.0 44.9 40.0
Side branch closure (%) 0 0 0
Transient vessel closure (%) 3.8 0 0
Recent MI 5 within 1–7 days. LVEF 5 left ventricular ejection fraction.
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Heart Assocation (ACC/AHA) criteria B2 or C lesions com-
pared with those beginning treatment on the day of the
procedure.
There were no major in-laboratory ischemic complications
(death, Q-wave MI, emergency bypass surgery) within the
study population. There were 28 procedure-related non–Q-
wave MIs as defined by an abnormal elevation in CKs with an
associated positive MB fraction. Fifteen events occurred in
those patients first receiving ticlopidine on the day of the
procedure (29%), 11 events in patients beginning ticlopidine 1
to 2 days before the procedure (14%) and only 2 events in
those pretreated for 3 or more days (5%) (chi-square for
trend 5 9.6, p 5 0.002) (Fig. 1). The incidence of non–Q-wave
MIs of various sizes among the patient groups is shown in
Table 2. Among subgroups of patients with or without recent
MI, saphenous vein stenting and B2 or C lesions, a similar
trend of increasing protection with a longer duration of
ticlopidine pretreatment was seen (Table 3).
Comparing the 45 patients who received $3 days of pre-
treatment with the 130 pretreated for ,3 days, the unadjusted
odds ratio for the risk of non–Q-wave MI was 0.18 (95%
confidence interval [CI] 5 0.04 to 0.78, p 5 0.01). After
adjusting for saphenous vein graft (SVG) and modified ACC/
AHA class, the adjusted odds ratio was 0.19 (95% CI 5 0.04 to
0.83, p 5 0.03). In a separate model adjusting for recent MI,
the adjusted odds ratio was 0.17 (95% CI 5 0.04 to 0.77, p 5
0.02).
In secondary analyses the population was divided into the
123 patients who received $1 day of ticlopidine pretreatment
and the 52 patients beginning ticlopidine on the day of the
procedure. The unadjusted odds ratio for the risk of a non–Q-
wave MI in the pretreated group was 0.32 (95% CI 5 0.14 to
0.72, p 5 0.005). After adjusting for SVG and modified
ACC/AHA class, the adjusted odds ratio was 0.31 (95% CI 5
0.13 to 0.72, p 5 0.006).
There were two major bleeding complications among the
study population. Both patients required a transfusion of 2 U
of packed red blood cells. One patient received ticlopidine
pretreatment for $3 days and the other was pretreated for 1 to
2 days before the procedure.
Discussion
This analysis of stent-treated patients is the first to suggest
that ticlopidine pretreatment of adequate duration to allow for
the development of near maximal platelet inhibition is associ-
ated with a markedly decreased incidence of procedure-related
non–Q-wave MI. The results are consistent with a “dose/
duration-effect,” that is, as the duration of pretreatment in-
creased from 1 to 3 or more days, with the associated devel-
opment of increasing antiplatelet protection by ticlopidine,
there was a time-dependent reduction in non–Q-wave MIs.
Mechanism. Thienopyridine compounds such as ticlopi-
dine and its more recently developed analog, clopidogrel,
selectively inhibit the platelet adenosine diphosphate (ADP)
receptor. They are inactive in vitro, and full antiplatelet action
of ticlopidine in vivo requires 3 to 5 days of oral administration
(19,23). Ticlopidine inhibits both ADP-induced alpha-granule
secretion and ADP-induced binding of fibrinogen to the
GPIIb/IIIa complex without directly interfering with the
GPIIb/IIIa receptor site (24). Although the thienopyridines do
not completely prevent fibrinogen binding and platelet aggre-
gation as do the direct GPIIb/IIIa inhibitors, recent studies
suggest that they inhibit binding to an extent that impairs the
formation of the platelet-to-platelet contacts necessary for
Figure 1. Incidence of procedure-related non–Q-wave MI in patient
groups based on the duration of ticlopidine pretreatment. Chi-squared
for trend, p 5 0.002.













0 days 19 2 2 6
1–2 days 11.4 1.3 0 1.3
$3 days 2.2 2.2 0 0
CK 5 creatinine kinase; MI 5 myocardial infarction.
Table 3. Frequency of Procedure-Related Non–Q-Wave MI
According to Duration of Pretreatment With Ticlopidine: Results of
Stratified Analyses
Patients









With SVG 46 23 0 5.5 0.02
Without SVG 23 10 6 4.3 0.04
With recent MI 20 17 0 0.6 0.43
Without recent MI 31 14 5 9.2 0.002
With B2 or C lesions 28 14 11 2.1 0.15
With A or B1 lesions 30 14 0 8.3 0.004
Recent MI 5 within 1–7 days. MI 5 myocardial infarction; SVG 5
saphenous vein graft.
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normal thrombus growth and stabilization (25). Animal studies
evaluating the combination of ticlopidine and aspirin have
demonstrated a synergistic antithrombotic effect (18,26), and a
similar interaction has been confirmed in humans (17,27).
The time-dependent development of improved antithrom-
botic effects in patients pretreated with ticlopidine and aspirin
have been confirmed in several clinical studies (17,28,29).
Rupprecht et al. (17) demonstrated that only patients treated
with both ticlopidine and aspirin, compared with either agent
alone, experienced a significant reduction in collagen-induced
platelet aggregation by 7 days of therapy. In another study by
Gregorini et al. (28), both thrombin generation and platelet
activation were significantly reduced before and after PTCA in
patients receiving $72 h of ticlopidine pretreatment, but not in
those pretreated for #24 h. As previous studies have demon-
strated a significant association between markers of platelet
activation before PTCA and acute ischemic complications,
these results support a basis for our findings and suggest a
greater clinical role for combined antiplatelet therapy before
all percutaneous coronary revascularization procedures (30).
The beneficial role of platelet inhibition in PTCA has been
consistently demonstrated in a number of studies of GPIIb/IIIa
inhibitors (7–11). Cost, however, remains a major limitation to
the widespread use of adjunctive GPIIb/IIIa inhibition therapy
during percutaneous interventions. Combination antiplatelet
therapy with ticlopidine or clopidogrel may prove to be an
effective, low cost alternative in specific subgroups of patients
able to begin therapy prior to the procedure.
Study limitations. Although all data were obtained pro-
spectively, this was an observational study and therefore suffers
from all the potential limitations of such a study. Despite
attempting to control for baseline differences between patient
groups, there are potentially other, unmeasured differences in
baseline risk factors that may have confounded the association
between duration of ticlopidine pretreatment and the inci-
dence of periprocedural MI.
For this study, the definition of a procedural non–Q-wave
MI was defined as any abnormal increase in CK with a positive
MB fraction. Although elevations of this level are associated
with an increased risk of an adverse long-term outcome (31), a
recent consensus statement defined a procedure-related MI as
an elevation of three times the laboratory normal (3).
The study sample is quite small with data collected over 1
year ago. At the time these patients were being treated, prepro-
cedural ticlopidine was not routinely used at our institution.
Conclusions. The association we observed between dura-
tion of ticlopidine pretreatment and risk of procedure-related
MI meets those of a valid clinical epidemiologic relationship.
The association was strong, with a nearly 80% reduction in risk
noted as the duration of therapy increased. A temporal
dose-response relationship was demonstrated. The association
persisted even after adjusting for potential confounders. Be-
cause all data were obtained routinely, uniformly and prospec-
tively among all potentially eligible patients, we doubt a major
selection or ascertainment bias exists. The relationship is
biologically plausible and is consistent with previous work.
Ticlopidine and aspirin provide synergistic platelet inhibi-
tory effects. When combination therapy is begun early enough
before coronary stenting to allow for the development of
ticlopidine’s maximal platelet inhibitory effects, there appears
to be an associated marked decrease in the incidence of
procedural non–Q-wave MIs. Randomized, prospective studies
are now needed to define the optimal dosing regimens and the
degree of clinical benefit achieved by pretreatment with this
kind of dual antiplatelet therapy.
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